ZP2307, a novel, cyclic PTH(1-17) analog that augments bone mass in ovariectomized rats

Bone

Volumn 48, Issue 6, 2011, Pages 1319-1327

  Neerup, Trine S R ^a   Stahlhut, Martin ^a,d   Petersen, Jørgen S ^a,e   Daugaard, Jens R ^a   Jensen, Jens Erik B ^b   Peng, ZhiQi ^c   Morko, Jukka ^c   Thorkildsen, Christian ^a  

^a Zealand Pharma AS   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c Pharmatest Services Ltd   (Finland)

^d LEO PHARMA A S   (Denmark)

^e MERCK SERONO S A   (Switzerland)

Author keywords

Histomorphometry; Ionized free serum calcium; Osteoporosis; OVX; Parathyroid hormone analog

Indexed keywords

CALCIUM; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE[1-34]; UNCLASSIFIED DRUG; ZP 2307;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE MASS; BONE STRENGTH; BONE STRUCTURE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; FEMUR; FEMUR HEAD; FEMUR SHAFT; HYPERCALCEMIA; LUMBAR VERTEBRA; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSTEOBLAST; OVARIECTOMY; RAT;

ABSORPTIOMETRY, PHOTON; ANIMALS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CYCLIC AMP; FEMALE; ORGAN SIZE; OVARIECTOMY; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RATS; RATS, INBRED F344; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79955916568     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.02.019     Document Type: Article

References (35)

1. Seeman E., Delmas P.D. Bone quality-the material and structural basis of bone strength and fragility. N. Engl. J. Med. 2006, 354:2250-2261.
2. Lane J.M., Russell L., Khan S.N. Osteoporosis. Clin. Orthop. Relat. Res. 2000, 139-150.
3. Christiansen C. Osteoporosis: diagnosis and management today and tomorrow. Bone 1995, 17:513S-516S.
4. Cummings S.R., Nevitt M.C., Browner W.S., Stone K., Fox K.M., Ensrud K.E., Cauley J., Black D., Vogt T.M. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 1995, 332:767-773.
5. van der Klift M., de Laet C.E., McCloskey E.V., Johnell O., Kanis J.A., Hofman A., Pols H.A. Risk factors for incident vertebral fractures in men and women: the Rotterdam Study. J. Bone Miner. Res. 2004, 19:1172-1180.
6. Li M., Healy D.R., Li Y., Simmons H.A., Gao F., Ke H.Z., Lu B., Owen T.A., Thompson D.D. A comparison of the anabolic effects of rat and bovine parathyroid hormone (1-34) in ovariectomized rats. J. Musculoskelet. Neuronal Interact. 2001, 2:77-83.
7. Liu C.C., Kalu D.N., Salerno E., Echon R., Hollis B.W., Ray M. Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone. J. Bone Miner. Res. 1991, 6:1071-1080.
8. Fukushima T., Nitta T., Furuichi H., Izumo N., Fukuyama T., Nakamuta H., Koida M. Bone anabolic effects of PTH(1-34) and salmon calcitonin in ovariectomy- and ovariectomy-steroid-induced osteopenic rats: a histomorphometric and biomechanical study. Jpn J. Pharmacol. 2000, 82:240-246.
9. Martin T.J., Quinn J.M., Gillespie M.T., Ng K.W., Karsdal M.A., Sims N.A. Mechanisms involved in skeletal anabolic therapies. Ann. NY Acad. Sci. 2006, 1068:458-470.
10. Rosen C.J. What's new with PTH in osteoporosis: where are we and where are we headed?. Trends Endocrinol. Metab. 2004, 15:229-233.
11. Greenspan S.L., Bone H.G., Ettinger M.P., Hanley D.A., Lindsay R., Zanchetta J.R., Blosch C.M., Mathisen A.L., Morris S.A., Marriott T.B. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 2007, 146:326-339.
12. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., Mitlak B.H. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001, 344:1434-1441.
13. Murrills R.J., Matteo J.J., Samuel R.L., Andrews J.L., Bhat B.M., Coleburn V.E., Kharode Y.P., Bex F.J. In vitro and in vivo activities of C-terminally truncated PTH peptides reveal a disconnect between cAMP signaling and functional activity. Bone 2004, 35:1263-1272.
14. Rhee Y., Lee W., Lee E.J., Ma S., Park S.Y., Lim S.K. In vitro and in vivo effect of parathyroid hormone analogue (1-14) containing -amino-iso-butyric acid residue (Aib)1,3. Yonsei Med. J. 2006, 47:214-222.
15. Goltzman D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch. Biochem. Biophys. 2008, 473:218-224.
16. Verhaar H.J., Lems W.F. PTH-analogs: comparable or different?. Arch. Gerontol. Geriatr. 2009, 49:e130-e132.
17. Luck M.D., Carter P.H., Gardella T.J. The (1-14) fragment of parathyroid hormone (PTH) activates intact and amino-terminally truncated PTH-1 receptors. Mol. Endocrinol. 1999, 13:670-680.
18. Shimizu N., Dean T., Khatri A., Gardella T.J. Amino-terminal parathyroid hormone fragment analogs containing alpha, alpha-di-alkyl amino acids at positions 1 and 3. J. Bone Miner. Res. 2004, 19:2078-2086.
19. Shimizu M., Potts J.T., Gardella T.J. Minimization of parathyroid hormone. Novel amino-terminal parathyroid hormone fragments with enhanced potency in activating the type-1 parathyroid hormone receptor. J. Biol. Chem. 2000, 275:21836-21843.
20. Shimizu N., Guo J., Gardella T.J. Parathyroid hormone (PTH)-(1-14) and -(1-11) analogs conformationally constrained by alpha-aminoisobutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 receptor. J. Biol. Chem. 2001, 276:49003-49012.
21. Whitfield J.F., Morley P., Willick G.E., Isaacs R.J., MacLean S., Ross V., Barbier J.R., Divieti P., Bringhurst F.R. Lactam formation increases receptor binding, adenylyl cyclase stimulation and bone growth stimulation by human parathyroid hormone (hPTH)(1-28)NH2. J. Bone Miner. Res. 2000, 15:964-970.
22. Whitfield J.F., Morley P., Willick G., Langille R., Ross V., MacLean S., Barbier J.R. Cyclization by a specific lactam increases the ability of human parathyroid hormone (hPTH)-(1-31)NH2 to stimulate bone growth in ovariectomized rats. J. Bone Miner. Res. 1997, 12:1246-1252.
23. Whitfield J.F., Morley P., Willick G., MacLean S., Ross V., Isaacs R.J., Barbier J.R. Comparison of the abilities of human parathyroid hormone (hPTH)-(1-34) and [Leu27]-cyclo(Glu22-Lys26)-hPTH-(1-31)NH2 to stimulate femoral trabecular bone growth in ovariectomized rats. Calcif. Tissue Int. 1998, 63:423-428.
24. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., Ott S.M., Recker R.R. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 1987, 2:595-610.
25. Osterman T., Lauren L., Kuurtamo P., Hannuniemi R., Isaksson P., Kippo K., Peng Z., Vaananen H.K., Sellman R. The effect of orally administered clodronate on bone mineral density and bone geometry in ovariectomized rats. J. Pharmacol. Exp. Ther. 1998, 284:312-316.
26. Frolik C.A., Black E.C., Cain R.L., Satterwhite J.H., Brown-Augsburger P.L., Sato M., Hock J.M. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 2003, 33:372-379.
27. Bisello A., Nakamoto C., Rosenblatt M., Chorev M. Mono- and bicyclic analogs of parathyroid hormone-related protein. 1. Synthesis and biological studies. Biochemistry 1997, 36:3293-3299.
28. Cheng Z., Yao W., Zimmermann E.A., Busse C., Ritchie R.O., Lane N.E. Prolonged treatments with anti-resorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen deficient osteoporotic rats. J. Bone Miner. Res. 2009, 1-43.
29. Lane N.E., Yao W., Kinney J.H., Modin G., Balooch M., Wronski T.J. Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J. Bone Miner. Res. 2003, 18:2105-2115.
30. Li M., Liang H., Shen Y., Wronski T.J. Parathyroid hormone stimulates cancellous bone formation at skeletal sites regardless of marrow composition in ovariectomized rats. Bone 1999, 24:95-100.
31. Yao W., Hadi T., Jiang Y., Lotz J., Wronski T.J., Lane N.E. Basic fibroblast growth factor improves trabecular bone connectivity and bone strength in the lumbar vertebral body of osteopenic rats. Osteoporos. Int. 2005, 16:1939-1947.
32. Stewart A.F., Cain R.L., Burr D.B., Jacob D., Turner C.H., Hock J.M. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J. Bone Miner. Res. 2000, 15:1517-1525.
33. Iwaniec U.T., Moore K., Rivera M.F., Myers S.E., Vanegas S.M., Wronski T.J. A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats. Osteoporos. Int. 2007, 18:351-362.
34. Ma Y.L., Bryant H.U., Zeng Q., Schmidt A., Jee W.S., Sato M. Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats. J. Bone Miner. Metab. 2005, 23(Suppl):62-68.
35. Neerup TSR, Duus J, Meier S, Petersen B, Thulstrup PW, Bukh C, Knudsen CB, Stahlhut M. Structure-activity relationship of novel, cyclic PTH(1-17) analogs, (in preparation).